OSPred Tool: A Digital Health Aid for Rapid Predictive Analysis of Correlations Between Early End Points and Overall Survival in Non–Small-Cell Lung Cancer Clinical Trials

Overall survival (OS) is the gold standard end point for establishing clinical benefits in phase III oncology trials. However, these trials are associated with low success rates, largely driven by failure to meet the primary end point. Surrogate end points such as progression-free survival (PFS) are...

Descripción completa

Detalles Bibliográficos
Autores principales: Shameer, Khader, Zhang, Youyi, Prokop, Andrzej, Nampally, Sreenath, N., Imran Khan A., Weatherall, Jim, Iacona, Renee Bailey, Khan, Faisal M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
Statistics in Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067362/
https://www.ncbi.nlm.nih.gov/pubmed/35467964
http://dx.doi.org/10.1200/CCI.21.00173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9067362/
https://www.ncbi.nlm.nih.gov/pubmed/35467964
http://dx.doi.org/10.1200/CCI.21.00173

Ejemplares similares